|1.||Jain, Rahul: 9 articles (03/2015 - 03/2003)|
|2.||Nayyar, Amit: 6 articles (05/2009 - 03/2003)|
|3.||Hua, Duy H: 4 articles (02/2013 - 06/2008)|
|4.||Nguyen, Thu A: 4 articles (01/2012 - 06/2008)|
|5.||Coutinho, Evans: 4 articles (05/2009 - 02/2006)|
|6.||Malde, Alpeshkumar: 3 articles (01/2007 - 02/2006)|
|7.||Egan, Timothy J: 2 articles (09/2015 - 11/2010)|
|8.||Smith, Peter J: 2 articles (09/2015 - 03/2015)|
|9.||Patel, Sanjay R: 2 articles (03/2015 - 05/2009)|
|10.||Rodrigues, Cecília M P: 2 articles (01/2015 - 10/2013)|
12/01/2005 - "We report in this study the in vivo efficacy of nine 2-substituted quinolines on the Leishmania amazonensis cutaneous infection murine model and on the Leishmania infantum and Leishmania donovani visceral infection murine models. "
05/15/1989 - "There is still further clinical study required regarding the efficacy of quinolines in urogenital infections with chlamydiae."
11/17/2003 - "Synthesis and biological evaluation of substituted quinolines: potential treatment of protozoal and retroviral co-infections."
02/28/2001 - "Macrolides were more sensitive for Uu infection, and quinolines were more sensitive for Mh infection, while the mixed infection of Mh and Uu had resistance to most antibiotics."
12/01/2005 - "Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases."
04/01/2013 - "Quinolines as chemotherapeutic agents for leishmaniasis."
01/01/2006 - "Thus, we have shown the real interest of these quinolines which could be favourably compared with pentamidine, which is currently the reference product, and to consider the use of these quinolines in the treament of the leishmaniasis."
01/01/2005 - "Thus, we have shown the real interest of these quinolines which could be favourably compared with pentamidine, which is currently the reference p roduct, and to consider the use of these quinolines in the treament of the leishmaniasis."
08/01/2010 - "Several new compounds and formulations have displayed promising efficacy in animal models of leishmaniasis, including the 8-aminoquinoline NPC1161, a series of bis-quinolines, DB766, rhodacyanine dyes, amiodarone, and an oral formulation of amphotericin B. "
11/01/1996 - "In vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by Leishmania amazonensis."
11/17/2003 - "We report the synthesis of substituted quinolines and their in vitro biological evaluation against the causal agents of cutaneous leishmaniasis, visceral leishmaniasis, African trypanosomiasis and Chagas' disease. "
|4.||Rheumatic Diseases (Rheumatism)
|3.||N- (4- (3- chloro- 4- (2- pyridinylmethoxy)anilino)- 3- cyano- 7- ethoxy- 6- quinolyl)- 4- (dimethylamino)- 2- butenamide
|4.||1,4- dihydro- 7- (3- methoxy- 4- methylamino- 1- pyrrolidinyl)- 4- oxo- 1- (2- thiazolyl)- 1,8- naphthyridine- 3- carboxylic acid
|6.||DNA (Deoxyribonucleic Acid)
|8.||Type II DNA Topoisomerases (Topoisomerase II)
|1.||Drug Therapy (Chemotherapy)